Abstract
Introduction Dynamic tools and methods to assess the ongoing transmission potential of COVID-19 in India are required. We aim to estimate time-dependent transmissibility of COVID-19 for India using a reproducible framework.
Methods Daily COVID-19 case incidence time series for India and its states was obtained from https://api.covid19india.org/ and pre-processed. Bayesian approach was adopted to quantify transmissibility at a given location and time, as indicated by the instantaneous reproduction number (Reff). Analysis was carried out in R version 4.0.2 using “EpiEstim_2.2-3” package. Serial interval distribution was estimated using “uncertain_si” algorithm with inputs of mean, standard deviation, minimum and maximum of mean serial interval as 5.1, 1.2, 3.9 and 7.5 days respectively; and mean, standard deviation, minimum, and maximum of standard deviations of serial interval as 3.7, 0.9, 2.3, and 4.7 respectively with 100 simulations and moving average of seven days.
Results A total of 9,07,544 cumulative incident cases till July 13th, 2020 were analysed. Daily COVID-19 incidence in the country was seen on the rise; however, transmissibility showed a decline from the initial phases of COVID-19 pandemic in India. The maximum Reff reached at the national level during the study period was 2.57 (sliding week ending April 4th, 2020). Reff on July 13th, 2020 for India was 1.16 with a range from 0.59 to 2.98 across various states/UTs.
Conclusion Reff provides critical feedback for assessment of transmissibility of COVID-19 and thus is a potential dynamic decision support tool for on-ground public health decision making.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Since the study involved secondary data analysis with the publicly available secondary datasets, Clinical Trail Registration was not mandated.
Funding Statement
Authors declare that we have not received any external funding for this research work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is an analysis of secondary data extracted from the publicly available resources, and it does not involve any individual identification details. So, the Institutional Ethics Committee approval was not mandated.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study is an analysis of secondary data extracted from the publicly available resources (https://api.covid19india.org/). The R codes used for analysis shall be shared with individual researchers on on request.